Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:advocates_for |
health organizations
required before administration |
| gptkbp:appointed_by |
injection
|
| gptkbp:approves |
gptkb:WHO
|
| gptkbp:associated_with |
herd immunity
reduction in polio outbreaks |
| gptkbp:clinical_trial |
conducted before approval
|
| gptkbp:collaborated_with |
other vaccines in combination vaccines
|
| gptkbp:contraindication |
severe allergic reactions
|
| gptkbp:contributed_to |
global health security
|
| gptkbp:country |
many countries worldwide
|
| gptkbp:developed_by |
gptkb:Jonas_Salk
|
| gptkbp:dosage_form |
multiple doses required
|
| gptkbp:first_introduced |
gptkb:1955
|
| gptkbp:healthcare |
significantly reduced polio cases
|
| gptkbp:historical_event |
developed in the 20th century
|
| https://www.w3.org/2000/01/rdf-schema#label |
inactivated polio vaccine
|
| gptkbp:influenced_by |
public health policies
|
| gptkbp:influences |
vaccine policy decisions
|
| gptkbp:is |
a key component of polio eradication strategy.
|
| gptkbp:is_available_on |
single antigen vaccine
|
| gptkbp:is_compared_to |
live attenuated vaccine
oral polio vaccine |
| gptkbp:is_effective_against |
high
|
| gptkbp:is_monitored_by |
health authorities
|
| gptkbp:is_studied_in |
epidemiological research
|
| gptkbp:is_used_for |
prevention of polio
|
| gptkbp:is_vulnerable_to |
induces immune response
|
| gptkbp:manufacturer |
pharmaceutical companies
|
| gptkbp:notable_feature |
does not cause disease
|
| gptkbp:notable_work |
extensive studies on safety and efficacy
|
| gptkbp:part_of |
routine immunization schedule
polio vaccination schedule |
| gptkbp:produced_by |
virus inactivation
|
| gptkbp:receives_funding_from |
government health programs
|
| gptkbp:released_in |
healthcare facilities
|
| gptkbp:requires |
cold chain logistics
booster doses trained healthcare personnel for administration |
| gptkbp:safety_features |
generally safe
|
| gptkbp:side_effect |
mild fever
|
| gptkbp:storage |
refrigeration needed
|
| gptkbp:strategic_importance |
polio eradication efforts
|
| gptkbp:suitable_for |
gptkb:Person
gptkb:CDC WHO for immunization |
| gptkbp:target_audience |
infants and young children
|
| gptkbp:targets |
gptkb:poliomyelitis
|
| gptkbp:type |
inactivated vaccine
|
| gptkbp:used_in |
global immunization programs
|
| gptkbp:bfsParent |
gptkb:Polio_Plus
gptkb:vaccine gptkb:GPEI gptkb:circulating_vaccine-derived_poliovirus |
| gptkbp:bfsLayer |
4
|